VIR - NASDAQ
Vir Biotechnology, Inc.
$8.77
+0.34%Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
At a Glance
Live SnapshotVir Biotechnology, Inc. Management Team
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Chief Executive Officer & Director
Compensation
$4,788,853
Dr. Lawrence Corey M.D.
Co-Founder & Scientific Advisor
Dr. Louis J. Picker M.D.
Co-Founder & Scientific Advisor
Mr. Jason O'Byrne M.B.A.
Executive Vice President & Chief Financial Officer
Compensation
$280,492
Dr. Mark D. Eisner M.D., M.P.H.
Executive Vice President & Chief Medical Officer
Compensation
$978,420
Dr. Jennifer Eileen Towne Ph.D.
Executive Vice President & Chief Scientific Officer
Dr. Maninder Hora Ph.D.
Executive Vice President & Chief Technical Operations Officer
Ms. Vanina de Verneuil J.D.
Executive Vice President, General Counsel & Corporate Secretary
Compensation
$1,095,136
Mr. Toby Medaris
Senior Vice President of Human Resources
Mr. Brent Sabatini
Senior Vice President, Principal Accounting Officer & Chief Accounting Officer
Vir Biotechnology, Inc. Insider Positioning
During the last 12 months, insiders have sold $21.02M worth of VIR shares, with no buying activity reported.
3 Months
0
0.00
127.8K
1.19M
-1.2M
-$1.19M
3-6 Months
0
0.00
139.0K
1.15M
-1.2M
-$1.15M
6-9 Months
0
0.00
3.0M
18.29M
-18.3M
-$18.29M
9-12 Months
0
0.00
76.4K
388.50K
-389K
-$389K
Top Buyers
No buying activity
Top Sellers
Svf Endurance (Cayman) Ltd
10 Percent Owner
$17.85M
Sato Vicki L
Director
$2.06M
De Backer Marianne
Director, Officer: President And Ceo
$806K
Sabatini Brent
Officer: Svp, Chief Accounting Officer
$99K
Eisner Mark
Officer: Evp And Chief Medical Officer
$72K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $21.02M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
VIR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 16, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 17, 2025 | May 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 19, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 07, 2023 | April 07, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 07, 2022 | May 20, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 06, 2021 | May 20, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 06, 2020 | May 20, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.